Skip to main content

Successful Value Retention with Effective Loss of Exclusivity (LoE) Management

Ruven Remo Eul | Principal | Marbls
The Life Sciences industry is constantly evolving, driven by innovations, market dynamics, and regulatory changes. One critical aspect that often goes overlooked is the management of Loss of Exclusivity (LOE). LOE represents a pivotal point in a product's lifecycle when market exclusivity ends, opening the door to generic competition. Unfortunately, many companies fail to proactively plan and manage their LOE transitions, leaving them vulnerable to immense revenue erosion and market share loss.
Sign in and download this insight
Ruven is a Principal at Marbls based out of Switzerland and has worked more than 16 years in Life Sciences in European and International markets with a primary focus in Pricing, Contracting, Tendering and Commercial Excellence. Ruven began his early career working in industry for Top 5 pharmaceutical manufacturers in tendering, contracting, and commercial effectiveness, from local to global roles. After which, Ruven joined HighPoint Solutions where he started and led consulting services in Europe for Global Pricing, Contracting and Tender Management. Ruven was responsible for developing teams, creating solutions, business development and project oversight as well as delivering services across clients from pharma, medical device to biosimilar & generic manufacturers. In addition, he was responsible for managing the international partnerships and Thought Leadership initiatives. Throughout the acquisition by IQVIA, Ruven became in charge of the legacy European HighPoint team. Ruven’s focus continues in Global Pricing & Tender Management as well as Commercial Excellence.